Moderate riskFDA DrugClass II

Bortezomib for Injection recalled for lack of sterility assurance

Reliance Life Sciences Private Limited is recalling bortezomib for injection, 3.5 mg per single-dose vial, manufactured for Somerset Therapeutics, for lack of sterility assurance. The recall covers 11,400 vials distributed nationwide. No injuries have been reported.

From the FDA notice · Read the official notice ↗

What to do

  1. Set aside any vials from the affected lots and do not use them.
  2. Check the NDC (70069-0836-01) and the lot and expiry dates against lots RBIH0125A (Jan 31, 2028), RBIH0225A (Feb 29, 2028), RBIH0325A (Feb 29, 2028), and RBIH0525A (Mar 31, 2028).
  3. Contact Somerset Therapeutics or Reliance Life Sciences for next steps. The notice does not say how to get a refund or replacement.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01
Sold in
Nationwide
Made for
All ages (0 months and older)

This recall covers 4 products — see all of them.

Details

Units affected
11,400 vials
Illnesses reported
None reported
Manufactured in
Ttc Area Of Midc, R - 282 Dhirubhai Ambani Life Sciences Centre; Thane Belapur Road, Navi Mumbai, N/A, India
Classification
Class II
Recall number
D-0673-2026

In the FDA's words

Description
Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01 Lack of Sterility Assurance Lot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028 Distribution: Nationwide in the USA Affected quantity: 11,400 vials
Hazard
Lack of Sterility Assurance

4 products in this recall

Somerset Therapeutics cancer drug vials recalled for lack of sterility

Reliance Life Sciences is recalling four injectable cancer drugs made for Somerset Therapeutics: Pemetrexed for Injection 100 mg and 500 mg vials, Bortezomib for Injection 3.5 mg vials, and Azacitidine for Injection 100 mg vials. The recall covers about 36,000 vials nationwide because of a lack of sterility assurance. No injuries have been reported.

The agency lists each product separately. Check every one you might have.

Related topics

SterilityDrugsSold nationwideMore from FDA Drug